Q1 FY27 Results: Revenue Up About 20% YoY, Turns Profitable; Going Concern Note
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec posted Q1 FY27 standalone revenue of Rs 13,471 lakh (up 20% YoY from Rs 11,225 lakh), turning profitable with a Rs 139 lakh net profit versus a Rs 670 lakh loss in Q1 FY26. Consolidated revenue rose to Rs 19,957 lakh with a Rs 220 lakh profit. The company booked Rs 274 lakh exceptional income from deferred consideration on a prior brand sale. Management flagged negative retained earnings of Rs 21,615 lakh raising a going concern uncertainty, but continues on a going concern basis citing higher long-term vaccine orders. 42nd AGM set for September 29, 2026.
Revenue rebound and return to profit are positives, but negative retained earnings create a going concern overhang. Watch vaccine order momentum and exceptional items.